About the Company
Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. The Company is leveraging its proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from its platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia.
Employees
350
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DCPH News
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?
Biogen Inc. belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Deciphera Pharmaceuticals, Inc. (DCPH), has gained 4.6% over the past month. More ...
Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)
Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. Currently, the analyst consensus on Protara ...
Analysts Offer Insights on Healthcare Companies: Black Diamond Therapeutics (BDTX) and I-MAB (IMAB)
Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. I-MAB has an analyst consensus of Strong Buy, ...
11 Best Small Cap Pharma Stocks to Invest In
For pharma stocks, these can be either big ticket and stable names such as Pfizer Inc. (NYSE:PFE) and Johnson & Johnson (NYSE ...
Madrigal Pharma: Rezdiffra Gets First FDA Approval For NASH
(RTTNews) - Madrigal Pharmaceuticals, Inc. (MDGL) announced that the U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) along with diet and exercise for the treatment of ...
Mirum gains as FDA accepts label expansion of liver disease drug
Mirum Pharmaceuticals' Livmarli receives FDA approval for the treatment of cholestatic pruritus in patients with progressive ...
Loading the latest forecasts...